AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA: A CASE REPORT

##article.authors##

  • Guljanat K ZHUNIS ЖШС «Ұлттық ғылыми онкология орталығы» Онкогематологиялық реанимациясы бар онкогематология және ТКМ орталығы Қазақстан Республикасы
  • Vadim M KEMAYKIN ЖШС «Ұлттық ғылыми онкология орталығы» Онкогематологиялық реанимациясы бар онкогематология және ТКМ орталығы Қазақстан Республикасы
  • Jamilya J SAPARBAY ЖШС «Ұлттық ғылыми онкология орталығы» Онкогематологиялық реанимациясы бар онкогематология және ТКМ орталығы Қазақстан Республикасы

##semicolon##

https://doi.org/10.31082/1728-452X-2020-221-222-11-12-49-52

##semicolon##

plasmablastic lymphoma##common.commaListSeparator## HIV-associated lymphomas##common.commaListSeparator## autologous hematopoietic stem cell transplantation

##article.abstract##

Plasmablastic lymphoma (PBL) is a disease that was originally described in 1997 as a distinct subtype of diffuse large B-cell lymphoma (DLBCL), which is more common in patients with HIV infection. It is characterized by extranodal lesions, the most common of which are the oral cavity, digestive tract, and skin3. No generally accepted chemotherapy protocol for the treatment of HIV-associated PBL has been developed. Early consolidation through autologous hematopoietic stem cell transplantation (auto-HSCT) may be a treatment option for advanced patients with concurrent use of highly active antiretroviral therapy (HAART).

Disease history. Patient B., 44 years old, with HIV-associated PBL-IV-stage according to AnnArbor with lesions of the alveolar process of the upper jaw, lymph nodes of the neck on the left, bronchopulmonary lymph nodes, and the lower lobe of the right lung, who after 6 courses of chemotherapy according to the standard CHOP regimen, autotransplantation of hematopoietic stem cells was performed in the first remission.

Conclusion. Our clinical experience correlates with the few studies on this issue. The patient received stem cell-supported high-dose chemotherapy (HDCT) and his life expectancy is 36 months.

##submission.citations##

Jorge J. Castillo, Michele Bibas, Roberto N. Miranda. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 9;125(15):2323-30. PMID: 25636338. DOI: 10.1182/blood-2014-10-567479

Carbone A. AIDS-related non-Hodgkin’s lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002; 33(4):392-404. PMID: 12055673. DOI: 10.1053/hupa.2002.124723

Andres Lopez, Pau Abrisqueta. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018 Oct 4;:8 63 –70. PMID: 31360094. PMCID: PMC6467349. DOI: 10.2147/BLCTT.S142814

Bibas M, Castillo JJ. Current knowledge on HIV-associated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014064. PMID: 25408850. PMCID: PMC 4235470. DOI: 10.4084/MJHID.2014.064

Alessandro Re, Chiara Cattaneo, Giuseppe Rossi. Hiv and Lymphoma: from Epidemiology to Clinical Management. Mediterr J

Hematol Infect Dis. 2019 Jan 1;11(1):e2019004. PMID: 30671210. PMCID: PMC6328036. DOI: 10.4084/MJHID.2019.004

Elyamany G, Mussaed E. Al, Alzahrani AM. Plasmablastic lymphoma: a review of current knowledge and future directions. Adv Hematol. 2015;2015:315289. PMID: 26357515. PMCID: PMC4555447. DOI: 10.1155/2015/315289

Kai Hübel, Alessandro Re, Ariane Boumendil, Herve Finel, et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2019 Oct:51(10):1625-1631. PMID: 30804486. DOI: 10.1038/s41409-

-0480-x

Monzr M Al-Malki, Jorge J Castillo, J Mark Sloan, Alessandro Re. Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: a review. Biol Blood Marrow Transplant. 2014 Dec;20(12):187784. PMID: 24946718. DOI: 10.1016/j.bbmt.2014.06.009

##submission.downloads##

##submissions.published##

2020-12-07

##issue.issue##

##section.section##

Articles